Jessamy Tiffen

Employment

• Centenary Institute Group Leader - Melanoma Epigenetics Lab
  2018 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (38)

• BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment
  Pigment Cell and Melanoma Research 2024 DOI: 10.1111/pcmr.13174
  +Save
• X and Y Differences in Melanoma Survival Between the Sexes
  Pigment Cell and Melanoma Research 2024 DOI: 10.1111/pcmr.13194
  +Save
• Correction: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response (Cellular and Molecular Life Sciences, (2023), 80, 6, (157), 10.1007/s00018-023-04799-4)
  Cellular and Molecular Life Sciences 2023 DOI: 10.1007/s00018-023-04825-5
  +Save
• Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response
  Cellular and Molecular Life Sciences 2023 DOI: 10.1007/s00018-023-04799-4
  +Save
• Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7
  Cellular and Molecular Life Sciences 2022 DOI: 10.1007/s00018-022-04452-6
  +Save
• Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells
  Cancers 2022 DOI: 10.3390/cancers14020323
  +Save
• Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma
  Journal of Investigative Dermatology 2022 DOI: 10.1016/j.jid.2021.09.030
  +Save
• A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
  Journal of Investigative Dermatology 2021 DOI: 10.1016/j.jid.2020.12.038
  +Save
• Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers
  Frontiers in Genetics 2021 DOI: 10.3389/fgene.2021.680633
  +Save
• Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma
  bioRxiv 2021 DOI: 10.1101/2021.08.23.457344
  +Save
• Sex bias of females in survival from cancer and infections. Is X the answer?
  British Journal of Cancer 2021 DOI: 10.1038/s41416-020-01245-1
  +Save
• Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma
  International Journal of Cancer 2020 DOI: 10.1002/ijc.33000
  +Save
• Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?
  Pigment Cell and Melanoma Research 2020 DOI: 10.1111/pcmr.12870
  +Save
• EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
  Jessamy C. Tiffen, Stuart J. Gallagher, Fabian V. Filipp +10 more
  Journal of Investigative Dermatology 2020 DOI: 10.1016/j.jid.2020.02.042
  +Save
• Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
  Frontiers in Immunology 2020 DOI: 10.3389/fimmu.2020.00372
  +Save
• Study of the female sex survival advantage in melanoma—a focus on x-linked epigenetic regulators and immune responses in two cohorts
  Cancers 2020 DOI: 10.3390/cancers12082082
  +Save
• Shedding light on dabrafenib-induced fevers in patients with melanoma
  The Lancet Oncology 2019 DOI: 10.1016/S1470-2045(19)30681-3
  +Save
• Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
  Abdullah Al Emran, Aniruddha Chatterjee, Euan James Rodger +4 more
  Trends in Immunology 2019 DOI: 10.1016/j.it.2019.02.004
  +Save
• HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
  International Journal of Cancer 2018 DOI: 10.1002/ijc.31199
  +Save
• Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
  Aniruddha Chatterjee, Euan James Rodger, Antonio Ahn +8 more
  iScience 2018 DOI: 10.1016/j.isci.2018.05.021
  +Save